UNSPSC 51331701: Amisulpride

This classification denotes a dopamine antagonist with the molecular formula C17H27N3O4S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 8110R61I4U, chemically known as benzamide, 4-amino-n-((1-ethyl-2-pyrrolidinyl)methyl)-5-(ethylsulfonyl)-2-methoxy- but generally known as amisulpride, which bears US NIH Compound Identifier 2159. European Medicines Agency schedules Amisulpride in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB05458MIG.

UNSPSC 51331701 Amisulpride is a Commodity code that nominally designates a single antipsychotic pharmaceutical product, but recent state and local procurement activity shows little alignment with this specific drug. The three recent opportunities tagged to this code reflect broader pharmaceutical procurement — naloxone and drug deactivation systems, direct-to-manufacturer prescription program development, and generic multi-source pharmaceutical and OTC product distribution — rather than amisulpride specifically. The mismatch suggests either classification error in the source data or that this code is used as a catch-all for pharmaceutical commodities beyond its nominal scope. State and local issuing bodies purchasing under or near this code include county health departments (Seminole County, Florida), state HHS commissions (Texas Health and Human Services Commission), and cooperative purchasing alliances serving multiple state and local jurisdictions (Minnesota Multistate Cooperative Purchasing Alliance, or MMCAP, administering on behalf of Minnesota and Oregon).

Recent procurement activity spans Florida, Texas, and the MMCAP multistate region (Minnesota and Oregon participating). Seminole County posted an IFB on June 30, 2026 (due July 26, 2023 per source) seeking 1,900 units of naloxone and 800 safe drug deactivation systems annually through quarterly deliveries, with a two-year initial term and one-year renewal option. The Texas HHS Commission issued an RFI posted April 3, 2026 to gather vendor capabilities on direct-to-manufacturer prescription programs outside traditional PBM and GPO channels, designed as a market-intelligence phase preceding formal RFP solicitation. MMCAP released an RFP posted January 20, 2026 (due March 26, 2026) for generic multi-source pharmaceuticals and OTC products with evaluation weighted 75 percent on price competitiveness, 10 percent on fixed pricing, and smaller percentages on compliance, EDI capability, and administrative-fee agreement, with contract awards effective July 1, 2026. The code shows recent activity but limited relevance to amisulpride procurement specifically.